Moderna’s Unexpected Q4 Profit TradingView News – TradingView

Key points:

Moderna reported a surprise profit in the fourth quarter of 2024, with earnings of 55 cents a share, a decrease from $3.61 a share in the same quarter a year ago. The company's net income exceeded expectations, despite a decline in sales of its Covid-19 vaccine, Spikevax. Revenue for the quarter was $2.81 billion, down from $5.08 billion in the year-ago quarter, but above projections for $2.51 billion.

The company's Covid-19 vaccine netted $800 million in U.S. sales and another $2 billion in international markets. The quarter also included the recognition of $600 million in deferred revenue related to Gavi, the Vaccine Alliance, an international organization created to improve vaccine access for children in poor countries.

Moderna's cost-cutting efforts and deferred payments contributed to the surprise profit. The company also set out a commercial roadmap for its vaccines in Europe and its experimental respiratory syncytial virus (RSV) shot. Moderna expects a U.S. approval decision for its RSV vaccine by May 12 and plans to launch the RSV shot in Germany and Australia this year.

Data posted earlier this month showed the RSV vaccine was 63% effective at preventing RSV-related respiratory symptoms after 8.6 months, down from 84% at 3.3 months. Moderna also expects data from late-stage trials of its next generation COVID shot and its cytomegalovirus and COVID-flu combination vaccines this year.

Despite the decrease in earnings and revenue, Moderna reaffirmed its 2024 forecast of $4 billion in sales, the lowest figure for annual revenue since its COVID vaccine got U.S. emergency authorization in late 2020.

Excerpt from:

Moderna's Unexpected Q4 Profit TradingView News - TradingView